Tormere Analytics
OverviewStock ResearchPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Pricing
Privacy PolicyTerms of Service

ADAG

$3.31-5.16%

Adagene Inc.

Market Cap
$207M
Sector
Materials
Industry
Biotechnology
Beta
0.65
5yr monthly vs SPY
Price Chart
Loading…

Signals

Insider Velocity
24.9x
buying
Congress
—
recent trades
Short Volume
71%
W/W +43.6pp

Market & Alt Data

News
11
recent articles
Activist
13D
Luo
Analyst Consensus
Strong Buy
13 analysts
Velocity Score
24.85x
Current Rate (90d)
280.50/mo
Baseline Rate
0.00/mo
Unique Buyers (90d)
2
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-08-142026-08-18DO CUONG VDirectorPurchase2,000$3.75$8K2,000View
2026-08-052026-08-06Luo PeterDirector & Chief Executive OfficerPurchase279$3.65$1K68.2KView
2026-08-042026-08-06Luo PeterDirector & Chief Executive OfficerPurchase23.0K$3.65$84K68.0KView

Recent News

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Yahoo Finance · 2026-09-10
An old stock-market adage applies this month — how you should play it
MarketWatch · 2026-09-03
An old stock-market adage applies this month — how you should play it
Yahoo Finance · 2026-09-03
Adagene to Participate in Three Upcoming Investor Conferences
Yahoo Finance · 2026-08-20

Informational purposes only, not investment advice.

NextSource Materials reports positive feasibility study for Phase 2 expansion at Madagascar graphite mine
Yahoo Finance · 2026-07-27
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Yahoo Finance · 2026-06-05
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Yahoo Finance · 2026-05-19
Adagene to Participate in Two Upcoming Investor Conferences
Yahoo Finance · 2026-05-12
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer
Yahoo Finance · 2026-04-20
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Yahoo Finance · 2026-04-17
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
Yahoo Finance · 2026-04-14

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →
Pipeline
Phase 2
5 active trials · readout 2026-10